Lancet Neurology publishes Prana's PBT2 trial results

Prana research shows PBT2 reduces Abeta and improves cognition in mouse model

Rudolph Tanzi provides testimony on Alzheimer's in front of the Special Committee on Ageing

Early results from a 78-patient safety trial are promising for Prana's Alzheimer's compound.

Share offer to raise funds for Alzheimer's trial.

Renowned neuroscientist Colin Masters has won the annual $50,000 Victoria Prize.

Last year wasn't the best on record for the Australian biotechnology industry but this year and the next look much more promising. Share prices are up, investors are showing more interest and there are a lot of good stories to tell and sell.

Prana Biotechnology has raised $7.8 million in cash to add to its fund for a Phase IIa trial in human patients of its PBT2 compound for Alzheimer's disease.

Melbourne-based Prana Biotechnology has announced that it has received regulatory approval from Sweden's Medical Products Agency (MPA) to start a Phase IIa clinical trial of its proprietary lead compound, PBT2, in patients with early Alzheimer's disease.

When the news of remarkable results in a pre-clinical trial of a potential drug for Alzheimer's disease was released in July, the headlines screamed and the share price for Prana Biotechnology went through the roof. Graeme O'Neill probes the details.

Melbourne's Prana Biotechnology (ASX:PBT, Nasdaq:PRAN) has successfully completed a second phase I trial of its lead compound PBT2, under development as a therapy for Alzheimer's disease.